Selling, General & Administrative Expenses
The latest quarterly sg&a expense is $317.20 Million with a quarter-over-quarter change of -4.28%. Selling, General & Administrative (SG&A) expenses include all costs related to selling products and running the business that are not directly tied to production.
PODD SG&A Expense
Reported quarterly SG&A expense; no daily interpolation.
Current SG&A Expense
$317.20M
$317.20 Million
Quarter-over-Quarter Change
-4.28%
vs. $331.40M prior quarter
Historical Data
85
Quarters of data available
Quarterly SG&A Expense History
| Period | SG&A Expense | QoQ Change | % Change |
|---|---|---|---|
| Q1 2026 | $317.20M | $-14.20M | -4.28% |
| Q4 2025 | $331.40M | +$16.20M | +5.14% |
| Q3 2025 | $315.20M | +$57.50M | +22.31% |
| Q2 2025 | $257.70M | $-2.90M | -1.11% |
| Q1 2025 | $260.60M | $-400,000 | -0.15% |
| Q4 2024 | $261.00M | +$26.90M | +11.49% |
| Q3 2024 | $234.10M | +$11.60M | +5.21% |
| Q2 2024 | $222.50M | +$22.80M | +11.42% |
| Q1 2024 | $199.70M | $-13.10M | -6.16% |
| Q4 2023 | $212.80M | +$32.10M | +17.76% |
| Q3 2023 | $180.70M | +$2.00M | +1.12% |
| Q2 2023 | $178.70M | +$16.00M | +9.83% |
| Q1 2023 | $162.70M | +$18.40M | +12.75% |
| Q4 2022 | $144.30M | +$3.90M | +2.78% |
| Q3 2022 | $140.40M | $-34.00M | -19.50% |
| Q2 2022 | $174.40M | +$45.70M | +35.51% |
| Q1 2022 | $128.70M | +$7.00M | +5.75% |
| Q4 2021 | $121.70M | +$4.20M | +3.57% |
| Q3 2021 | $117.50M | +$1.20M | +1.03% |
| Q2 2021 | $116.30M | +$5.80M | +5.25% |
| Q1 2021 | $110.50M | $-19.60M | -15.07% |
| Q4 2020 | $130.10M | +$40.90M | +45.85% |
| Q3 2020 | $89.20M | +$8.40M | +10.40% |
| Q2 2020 | $80.80M | $-3.10M | -3.69% |
| Q1 2020 | $83.90M | +$2.63M | +3.23% |
| Q4 2019 | $81.28M | +$6.47M | +8.66% |
| Q3 2019 | $74.80M | $-1.00M | -1.32% |
| Q2 2019 | $75.80M | +$8.90M | +13.30% |
| Q1 2019 | $66.90M | +$1.33M | +2.04% |
| Q4 2018 | $65.56M | $-7.20M | -9.90% |
| Q3 2018 | $72.77M | +$13.82M | +23.45% |
| Q2 2018 | $58.95M | +$3.40M | +6.12% |
| Q1 2018 | $55.55M | $-5.95M | -9.67% |
| Q4 2017 | $61.49M | +$10.06M | +19.55% |
| Q3 2017 | $51.44M | +$1.47M | +2.94% |
| Q2 2017 | $49.97M | +$2.76M | +5.85% |
| Q1 2017 | $47.21M | $-1.83M | -3.74% |
| Q4 2016 | $49.04M | +$9.55M | +24.18% |
| Q3 2016 | $39.49M | +$697,000 | +1.80% |
| Q2 2016 | $38.79M | +$31,000 | +0.08% |
| Q1 2016 | $38.76M | $-17.70M | -31.35% |
| Q4 2015 | $56.46M | +$20.13M | +55.42% |
| Q3 2015 | $36.33M | +$3.83M | +11.77% |
| Q2 2015 | $32.51M | +$4.25M | +15.05% |
| Q1 2015 | $28.25M | $-3.39M | -10.71% |
| Q4 2014 | $31.64M | $-2.12M | -6.27% |
| Q3 2014 | $33.76M | $-608,000 | -1.77% |
| Q2 2014 | $34.37M | +$6.45M | +23.12% |
| Q1 2014 | $27.91M | +$1.53M | +5.79% |
| Q4 2013 | $26.39M | $-12.55M | -32.23% |
| Q3 2013 | $38.94M | +$11.46M | +41.69% |
| Q2 2013 | $27.48M | +$516,000 | +1.91% |
| Q1 2013 | $26.96M | +$1.41M | +5.51% |
| Q4 2012 | $25.56M | $-744,000 | -2.83% |
| Q3 2012 | $26.30M | $-27,000 | -0.10% |
| Q2 2012 | $26.33M | +$570,000 | +2.21% |
| Q1 2012 | $25.76M | +$971,000 | +3.92% |
| Q4 2011 | $24.79M | +$1.10M | +4.63% |
| Q3 2011 | $23.69M | +$1.07M | +4.73% |
| Q2 2011 | $22.62M | +$6.40M | +39.49% |
| Q1 2011 | $16.22M | +$1.53M | +10.45% |
| Q4 2010 | $14.68M | $-1.53M | -9.42% |
| Q3 2010 | $16.21M | +$1.01M | +6.62% |
| Q2 2010 | $15.20M | $-65,000 | -0.43% |
| Q1 2010 | $15.27M | $-677,000 | -4.25% |
| Q4 2009 | $15.95M | +$70,000 | +0.44% |
| Q3 2009 | $15.88M | $-467,000 | -2.86% |
| Q2 2009 | $16.34M | +$79,000 | +0.49% |
| Q1 2009 | $16.26M | $-586,000 | -3.48% |
| Q4 2008 | $16.85M | +$365,000 | +2.21% |
| Q3 2008 | $16.48M | +$95,000 | +0.58% |
| Q2 2008 | $16.39M | +$2.63M | +19.09% |
| Q1 2008 | $13.76M | +$3.20M | +30.25% |
| Q4 2007 | $10.57M | +$3.03M | +40.28% |
| Q3 2007 | $7.53M | +$1.33M | +21.44% |
| Q2 2007 | $6.20M | +$438,000 | +7.60% |
| Q1 2007 | $5.76M | +$1.07M | +22.80% |
| Q4 2006 | $4.69M | +$703,000 | +17.61% |
| Q3 2006 | $3.99M | +$3.99M | — |
| Q2 2006 | $0 | +$0 | — |
| Q1 2006 | $0 | +$0 | — |
| Q4 2005 | $0 | +$0 | — |
| Q3 2005 | $0 | +$0 | — |
| Q2 2005 | $0 | +$0 | — |
| Q1 2005 | $0 | — | — |
About Insulet Corp.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Ashley A. McEvoy